Call(WhatsApp Us)
+8615360806100Email Us
cherry@laeyo.comSee the factory by live video walkthrough
Book an on-site factory visit in GuangzhouMoving a men's face cleanser from one plant to another is a change-control event, not a file transfer. The INCI list can be identical and the product can still arrive thicker, thinner, harsher, less…
Moving a men’s face cleanser from one plant to another is a change-control event, not a file transfer. The INCI list can be identical and the product can still arrive thicker, thinner, harsher, less foamy, or unstable — because the water, the mixer geometry, the homogenizer energy, the raw-material grades and the fill line all changed at once. The job of the buyer is not to accept “same formula, same result.” It is to demand the evidence that proves equivalence: a signed golden reference, a bridged specification, stability and micro data on the new site’s bulk, and a packaging compatibility run on the actual tube or pump. This guide gives you the documents to request, the red lines not to cut, and a realistic timeline so you can qualify a new factory without discovering the problems after the first production run.
Even a “copy” formula behaves differently when four variables move. Map them before you talk price.
Because “clean” or “purifying” cannot be fully re-tested on every batch, qualified sites control performance through proxy metrics tied to the validated benefit — typically pH + viscosity + foam + sensory — tested per batch on approved methods, with a periodic performance study and revalidation triggered by any formula, process or raw-material change.
Everything downstream — testing cost, lead time, label artwork — is a consequence of these three. Lock them in writing, not in a call.
| Decision to lock | Why it drives cost and timeline | Evidence to request before paying a deposit |
|---|---|---|
| Target market(s) and claim set | Determines whether you need a CPSR and Responsible Person (EU), a filing (China), safety substantiation files (US), and which allergen declarations apply. A “global” launch multiplies documentation. | Written market list per SKU; regulatory route confirmation per market; draft claim list reviewed against finished-product evidence. |
| Golden reference sample + full specification | Without a signed reference, “matching the old product” has no measurable acceptance criteria and every trial becomes an opinion. | Retained golden sample (with storage conditions), full spec with test methods, and the previous site’s last three batch records. |
| Packaging and fill line | Viscosity must satisfy the pump or tube; incompatibility discovered after stability means repeating stability. | Component drawings, resin/material declaration, and a packaging compatibility protocol agreed before the pilot run. |
Send this list as a single request. A factory that cannot answer items in sections A and B is not ready for a transfer.
Ask the technical team to walk you through how the transferred formula behaves on their equipment, not how it behaved on yours.
A men’s face cleanser usually ships in a tube, an airless pump or a flip-top bottle, and each imposes constraints that stability testing alone will not catch.
Lead times below assume a cooperative factory and an existing formula. Compress documentation only where your market allows it.
| Phase | Buyer action | Factory action | Evidence output | Typical lead time |
|---|---|---|---|---|
| 1. Documentation and spec handoff | Share formula, spec, golden sample, market list, claim list | Review feasibility, gap-list open items | Signed technical feasibility review | 1–2 weeks |
| 2. Lab trial and matching | Approve or reject against golden reference | Produce lab batches, adjust process | Trial report with pH, viscosity, foam, sensory | 2–4 weeks |
| 3. Packaging lock | Confirm component and decoration | Order components, confirm fill window | Approved component drawing and specification | 3–6 weeks (component dependent) |
| 4. Pilot run | Attend or witness the run | Manufacture pilot bulk, fill pilot units | Pilot batch record and in-process data | 1–2 weeks |
| 5. Stability, micro, compatibility | Review data as it lands | Run accelerated stability, PET, compatibility | Stability report, PET report, compatibility report | 8–12 weeks (can overlap phase 6) |
| 6. Label and claims review | Approve artwork and claims matrix | Provide allergen data, claim support | Approved artwork with review record | 2–4 weeks |
| 7. Commercial run and handoff | Approve release | Manufacture, test, release | COA, batch record, retention sample, final document pack | 1–3 weeks |
Fastest safe path: compress lab trials to a single round if the first trial matches the golden reference on all proxy metrics, run stability and packaging compatibility in parallel, and pre-approve artwork during the pilot. Do not compress the PET or the compatibility run.
Standard path: two trial rounds with a one-week sensory evaluation between them, sequential stability start after pilot approval, and a second compatibility check on production-filled units. Adds roughly four to six weeks and removes most late-stage surprises.
| Symptom | Root cause | Prevention | Evidence to request |
|---|---|---|---|
| Bulk viscosity drifts between batches at the new site | Different homogenizer energy and cooling rate; raw-material grade change | Fix the process parameters in the master batch record and bridge the viscosity method | Process parameters with tolerances; method bridging report; three consecutive batch results |
| Product thins or discolours after eight weeks | Stability run performed on lab bulk, not production bulk, or only real-time data started after launch | Run accelerated stability on pilot or production bulk before commercial release | Accelerated and freeze–thaw report tied to the pilot batch number |
| Pump fails to prime, or doses unevenly | Viscosity outside the pump’s design window; air trapped during filling | Set a fill-viscosity window from the pump specification and test dose per stroke | Pump specification; dose-per-stroke and prime-time test results on filled units |
| Odour shift or panel cracking within weeks | Fragrance–plastic interaction not tested; incompatible resin or liner | Run compatibility on the actual bulk and component, stored at elevated temperature | Packaging compatibility report including odour, weight loss and visual inspection |
| Customs or retailer query on documentation | COA, SDS or allergen declaration missing, expired, or mismatched to the supplier actually used | Build a document pack per SKU before the first shipment and audit it quarterly | Current COA/SDS set matched to batch records; allergen calculation; GMP certificate with scope |
| Label rejected for an unsupported claim | Claims written by marketing after the artwork freeze, with no supporting test | Freeze the claim list before artwork and require a document reference per claim | Claims matrix signed by regulatory and QA |
| Micro out-of-spec on a single batch | Water system or filling hygiene issue masked by a passing PET | Trend per-batch micro counts and review water system validation | Water system validation report; per-batch micro results; deviation record |
Share the target market list per SKU and confirm the regulatory route for each.
Provide the full formula, specification and test methods for the transferred product.
Attach the golden reference sample with its storage conditions and date.
Confirm the last three batch records from the current site are available.
Lock the claim list before artwork and reject claims without a supporting document.
Confirm which raw materials, grades and suppliers will be used at the new site.
Request COA and SDS for every raw material from those named suppliers.
Request the completed change-control record covering spec, method, golden sample and AQL.
Approve the method bridging plan for pH, viscosity and foam before the first trial.
Confirm the process parameters: heating and cooling profile, homogenizer energy, pH stage.
Run pilot-scale bulk before any commercial-scale commitment.
Test pH, viscosity, foam and sensory on every pilot and validation batch.
Start accelerated stability and freeze-thaw on pilot bulk, not lab bulk.
Confirm preservative efficacy testing is planned on the transferred formula.
Send the packaging drawings and agree the compatibility protocol.
Test dose per stroke, prime time, leak and label adhesion on filled units.
Request the fragrance allergen declaration and the finished-product allergen calculation.
Review label artwork against the allergen data and the claim matrix.
Confirm the rework and reprocess policy includes risk assessment and QA approval.
Request GMP certificate scope and the latest audit summary for the specific site.
Agree the final documentation handoff list and the release sign-off.
Schedule a quarterly document review after launch.
Yes. Stability and microbiological performance belong to the bulk made at a specific site on specific equipment with that site’s water and hygiene controls. A report from the previous factory describes a different product. Accelerated stability, freeze–thaw and preservative efficacy testing on the new site’s pilot or production bulk are the minimum evidence for release.
Usually close, rarely identical without process adjustment. What matters is that the specification window accepts the new bulk and that the method is bridged — same spindle, speed and temperature for viscosity, and a defined foam method. If the product must work in an existing pump, set the fill-viscosity window from the pump specification and test dose per stroke on filled units.
Treat it as a documented change. A fragrance supplier change can alter the ingredient profile and the allergen picture, which means the safety report, filings and label warnings may all need review, and a tolerance re-test should be assessed rather than assumed unnecessary. Have the factory produce a change assessment that explicitly covers exposure, ingredient risk, warning text and post-market monitoring.
Plan on roughly 10 to 16 weeks for a straightforward transfer where the formula, components and claim set are already settled, with stability and compatibility running in parallel to artwork review. Component lead times and sequential stability can push this beyond 20 weeks. Any proposed timeline that skips preservative efficacy or packaging compatibility is not a shortcut — it is deferred risk.
Target markets, SKU count and formats, positioning, packaging direction and your launch date. With those five items a manufacturer can scope testing, components and capacity without a round of clarification emails.
Informational only, not legal or regulatory advice. Confirm market-specific obligations with your regulatory specialist or Responsible Person before artwork sign-off.
If you are transferring a men’s face cleanser or building a men’s care range from scratch, send your formula status, target markets, packaging direction and launch date in one message. You will get a scoped testing plan, a realistic transfer timeline and a documentation list matched to your markets — rather than a price with the evidence stripped out. Request a Quote.